Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.16.6837

Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand  

Siriaunkgul, Sumalee (Department of Pathology, Faculty of Medicine, Chiang Mai University)
Settakorn, Jongkolnee (Department of Pathology, Faculty of Medicine, Chiang Mai University)
Sukpan, Kornkanok (Department of Pathology, Faculty of Medicine, Chiang Mai University)
Srisomboon, Jatupol (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University)
Suprasert, Prapaporn (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University)
Kasatpibal, Nongyao (Faculty of Nursing, Chiang Mai University)
Khunamornpong, Surapan (Department of Pathology, Faculty of Medicine, Chiang Mai University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.16, 2014 , pp. 6837-6842 More about this Journal
Abstract
Background: Northern Thailand is a region with a high cervical cancer incidence. Combined high-risk HPV (hrHPV) DNA testing and cytology (co-testing) has increasingly gained acceptance for cervical cancer screening. However, to our knowledge, data from a population-based screening using co-testing have not been available in this region. This study therefore aimed to evaluate the performance of cytology and hrHPV test in women in northern Thailand. Materials and Methods: Cervical samples were collected for hybrid capture 2 (HC2) testing and liquid-based cytology from women aged 30 to 60 years who were residents in 3 prefectures of Chiang Mai in northern Thailand between May and September 2011. Women with positive cytology were referred to colposcopy, while women with positive for HC2 only were followed for 2 years. Results: Of 2,752 women included in this study, 3.0% were positive in both tests, 4.1% for HC2 only, and 1.3% had positive cytology only. At baseline screening, positive HC2 was observed in 70.6% among cytology-positive women compared with 4.3% among cytology-negative women. The prevalence of positive HC2 or cytology peaked in the age group 35-39 years and was lowest in the age group 55-60 years. High-grade squamous intraepithelial lesion or worse lesions (HSIL+) were histologically detected in 23.5% of women with positive baseline cytology and in 9.8% of women with positive baseline HC2 only on follow-up. All women with histologic HSIL+ had positive baseline HC2. Conclusions: The hrHPV test is superior to cytology in the early detection of high-grade cervical epithelial lesions. In this study, the prevalence of histologic HSIL+ on follow-up of women with positive hrHPV test was rather high, and these women should be kept under careful surveillance. In northern Thailand, hrHPV testing has a potential to be used as a primary screening test for cervical cancer with cytology applied as a triage test.
Keywords
Cervical cancer screening; liquid-based cytology; HPV DNA test; Thailand;
Citations & Related Records
Times Cited By KSCI : 8  (Citation Analysis)
연도 인용수 순위
1 Kantathavorn N, Kietpeerakool C, Suprasert P, et al (2008). Clinical relevance of atypical squamous cells of undetermined significance by the 2001 bethesda system: experience from a cervical cancer high incidence region. Asian Pac J Cancer Prev, 9, 785-8.
2 Katki HA, Schiffman M, Castle PE, et al (2013). Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis, 17, 56-63.   DOI
3 Kiatiyosnusorn R, Suprasert P, Srisomboon J, et al (2010). Highgrade histologic lesions in women with low-grade squamous intraepithelial lesion cytology from a region of Thailand with a high incidence of cervical cancer. Int J Gynaecol Obstet, 110, 133-6.   DOI   ScienceOn
4 Leinonen M, Kotaniemi-Talonen L, Anttila A, et al (2008). Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer, 123, 1344-9.   DOI
5 Li J, Huang R, Schmidt JE, Qiao YL (2013). Epidemiological features of human papillomavirus (HPV) infection among women living in mainland China. Asian Pac J Cancer Prev, 14, 4015-23.   과학기술학회마을   DOI
6 Massad LS, Einstein MH, Huh WK, et al (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 17, 1-27.
7 Ogilvie GS, Krajden M, van Niekerk DJ, et al (2012). Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer, 107, 1917-24.   DOI
8 Othman N, Othman NH (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9.   과학기술학회마을   DOI   ScienceOn
9 Pan QJ, Hu SY, Zhang X, et al (2013). Pooled analysis of the performance of liquid-based cytology in populationbased cervical cancer screening studies in china. Cancer Cytopathol, 121, 473-82.   DOI
10 Pandey S, Mishra M, Chandrawati (2012). Human papillomavirus screening in north Indian women. Asian Pac J Cancer Prev, 13, 2643-6.   과학기술학회마을   DOI   ScienceOn
11 Rai AK, Das D, Kataki AC, et al (2014). Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India. Asian Pac J Cancer Prev, 15, 861-5.   과학기술학회마을   DOI
12 Rashid RM, Dahlui M, Mohamed M, Gertig D (2013). Adapting the Australian system: is an organized screening program feasible in Malaysia?--an overview of cervical cancer screening in both countries. Asian Pac J Cancer Prev, 14, 2141-6.   DOI   ScienceOn
13 Ronco G, Giorgi-Rossi P, Carozzi F, et al (2006). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol, 7, 547-55.   DOI
14 Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74.   DOI   ScienceOn
15 Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.   DOI
16 Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural india. N Engl J Med, 360, 1385-94.   DOI   ScienceOn
17 Sharma M, Bruni L, Diaz M, et al (2013). Using HPV prevalence to predict cervical cancer incidence. Int J Cancer, 132, 1895-900.   DOI   ScienceOn
18 Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O (2010). Prevalence of high-risk human papillomavirus infection and cytologic results in Thailand. Asian Pac J Cancer Prev, 11, 1465-8.
19 Wang Y, Yu YH, Shen K, et al (2014). Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. Asian Pac J Cancer Prev, 15, 671-6.   과학기술학회마을   DOI
20 Zhao FH, Lin MJ, Chen F, et al (2010). Performance of highrisk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from china. Lancet Oncol, 11, 1160-71.   DOI   ScienceOn
21 Zorzi M, Del Mistro A, Farruggio A, et al (2013). Use of a highrisk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG, 120, 1260-7.   DOI
22 Carestiato FN, Silva KC, Dimetz T, Oliveira LH, Cavalcanti SM (2006). Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz J Infect Dis, 10, 331-6.
23 Arbyn M, Benoy I, Simoens C, et al (2009). Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev, 18, 321-30.   DOI
24 Arbyn M, Ronco G, Anttila A, et al (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 30, 88-99.   DOI
25 Bulkmans NW, Berkhof J, Rozendaal L, et al (2007). Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year followup of a randomised controlled implementation trial. Lancet, 370, 1764-72.   DOI   ScienceOn
26 Castle PE, de Sanjose S, Qiao YL, et al (2012). Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine, 30, 117-22.   DOI
27 Castle PE, Fetterman B, Poitras N, et al (2009). Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol, 113, 595-600.   DOI
28 Curado MP, Edwards B, Shin HR, et al (2007). Cancer incidence in five continents, Vol. IX. Lyon: IARC Scientific Publications No.160.
29 Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north american studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101.   DOI   ScienceOn
30 Cuzick J, Szarewski A, Cubie H, et al (2003). Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362, 1871-6.   DOI   ScienceOn
31 Dudding N, Crossley J (2013). Sensitivity and specificity of HPV testing: what are the facts? Cytopathology, 24, 283-8.
32 Ferreccio C, Barriga MI, Lagos M, et al (2013). Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. Int J Cancer, 132, 916-23.   DOI
33 Franceschi S, Herrero R, Clifford GM, et al (2006). Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer, 119, 2677-84.   DOI   ScienceOn
34 Herrero R, Hildesheim A, Bratti C, et al (2000). Populationbased study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 92, 464-74.   DOI   ScienceOn
35 Ito K, Tsunematsu M, Satoh K, Kakehashi M, Nagata Y (2013). Effectiveness of cervical cancer screening based on a mathematical screening model using data from the Hiroshima Prefecture Cancer Registry. Asian Pac J Cancer Prev, 14, 4897-902.   과학기술학회마을   DOI   ScienceOn
36 Jin XW, Lipold L, McKenzie M, Sikon A (2013). Cervical cancer screening: what's new and what's coming? Cleve Clin J Med, 80, 153-60.   DOI
37 Junyangdikul P, Tanchotsrinon W, Chansaenroj J, et al (2013). Clinical prediction based on HPV DNA testing by hybrid capture 2 (HC2) in combination with liquid-based cytology (LBC). Asian Pac J Cancer Prev, 14, 903-7.   과학기술학회마을   DOI
38 Sukvirach S, Smith JS, Tunsakul S, et al (2003). Populationbased human papillomavirus prevalence in lampang and Songkla, thailand. J Infect Dis, 187, 1246-56.   DOI   ScienceOn